Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
DPP4 inhibitors (DPP4i) are a class of newly developed antidiabetic drugs which preserve incretin hormones and promote postprandial insulin secretion. Although the cardiovascular effect of DPP4 inhibition has been substantially studied, the exact role of DPP4 in cardiovascular disease especially in...
Saved in:
Main Authors: | Jixin Zhong, Quan Gong, Aditya Goud, Srividya Srinivasamaharaj, Sanjay Rajagopalan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2015/606031 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
by: Sevin Demir, et al.
Published: (2016-01-01) -
Novel insight into the formation and inhibition mechanism of dipeptidyl peptidase-Ⅳ inhibitory peptides from fermented mandarin fish (Chouguiyu)
by: Daqiao Yang, et al.
Published: (2023-11-01) -
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial
by: Thananda Trakarnvanich, et al.
Published: (2021-01-01) -
The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
by: Pegah Yousefzadeh, et al.
Published: (2013-01-01) -
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
by: Seung Hee Choi, et al.
Published: (2017-01-01)